Inducible arginine ox idation and subsequent NO production by correspond ent synthase (iNOS) are im portant cellu lar answers to proinflammatory signals. Prolonged NO production has b een proved in higher organisms to cause stroke or sep ti c shock. Several cl asses of potent NOS inhibitors have been reported, most of them targe ting the a rginine binding site of the oxyge nase domain. He re w e disclose th e SAR and the rational design of potent and selective iNOS inhibitors which may be usefu l as antiinflammatory drugs.
Nitric oxide synthase Inflammation
Crys tal stru cture Stru cture-based design Selec tivity Inhibitor Nitri c oxide synthase (NOS; EC 1. 14.13 .39) generates the important ne urotransmitter and cytotoxic agent NO via oxidation of L-arginine. I Three major isoforms have been identified in mammals: ne uronal NOS (nNOS), inducible NOS (iNOS) and endotheli al NOS (eNOS). 2.3 They share 50-60% sequence id entity and have identical overall architecture. The known NOS enzymes are active as a homodimer, and each monomer is comprised of a catalytic N-terminal oxygenase domain, a C-terminal reductase domain and a calmodulin binding linker. The oxygenase dom ain (NOS ox ) binds th e substrates L-arginine and O 2 and contains th e two cofactors hem e and 5,6,7,8-(6R)-tetrahydrobiopterine (BH4) and a structural zinc ato m. Electron s are suppli ed to the O 2 bound heme from th e NADPH-binding redu ctase domain involving the cofactors FAD and FMN. 4 The constitutively expressed isoforms nNOS and eNOS are regulated by Ca 2 +jcalmodulin and produce low levels of NO (100-500 nmol jmg min) predominantly for both nerve function and blood pressure regulat ion, respectively. In co ntrast, the inducible isofo rm is controlled at the transcription level and ex pressed in res ponse to proinflammatory signals. s Because iNOS is often expressed at hi gh levels over longe r time periods, the overproduction of NO (1500 nmoljmg min) can lead to undiserable pathologies such as stroke and septic shock. Therefore, selective inhibi t ion of the inducible isoform ca n serve as a suitable strategy to target both acute and chronic inflammation. 6 Several classes of potent NOS inhibitors have been repo rted, most of them targeting the arginine binding site of the oxygenase domain (Table 1 ) .7 One major class of inhibitors are L-arginine analogues bea ring a guanidine, amidino or isothiourea group that mimi c the recognition of the guanidinium group of the substrate as confirmed by X-ray crystallography.s Amon g these, the weakly selective iNOS inhibitor N-iminoethyl -L -Iysin e (la, L-NIL) as its tetrai ole-amide acid prodrug (L-NIL-TA, SC-51) (lb, Fig. 1 ) has been demonstrated to red uce ex hal ed brea th nitric oxide in patients with mild asthma. However, ONO-1714 shows only 10-fold selectivity over eNOS and no selectivity over nNOS. II Since the arginine binding-site is highly conserved among the NOS isoenzymes, structure-based design of selective inhibitors remains a challenging problem. 12 -14 However, several substrate mimetics, like GW-274150 3, achieve isoform selectivity through additional interactions outside of the catalytic site. l s . 16 Both L-arginine ana logues L-NIL-TA Ib and GW-274150 3, respectively, have been tested in clinical phase II for the oral treatment of migraine, rheumatoid arthritis (RA), osteoarthritis (OA), chronic obstructive pulmonary disease (COPD), asthma and allergic rhinitis. However, no further development has been reported for both compounds, A series of spirocyclic am idines such as 4 (AR-Cl 02222) were reported as highly potent and selective iNOS-inhibitors with good oral activity.1 7 Several groups have identified 2-aminopyridines such as 5 as potent NOS inhibitors revealing their potential to mimic the basic ami dine or guanidine group in L-arginine analogues. 18 In another study, N-substituted 4-methoxy-2-aminopyridines such as 6 (AR-C133057XX) demonstrated both high potency and selectivity as iNOS inhibitors. 19 Lately, several papers showed renewed interest on selective iNOS i nhibitors.2°- 22 In a screening campaign conducted on our corporate compound library, 2-( 4-methoxypyridin-2-ylmethylsulfanyl)-3H-imidazo[ 4, 5 -b] pyridine (7) has been identified as potent iNOS inhibitor (plC so = 6.94, Table 2 ). NOS activity was measured by quantification of [3H] L-arginine conversion to [3H] L-citrulline. 23 The selectivity profile of 7 (nNOS: plC so = 5.47; eNOS: plC so = 4.27) provided an id ea l starting point for further hit-to-Iead optimization. Radioligand binding experiments demonstrated, that 13, a carbo analogue of 7 (Ta bl e 3 ), acts as a competitive inhibitor with respect to L-arginine? 3 This observation suggests that 7, and the entire SAR family, interact with the L-arginine-binding site within iNOS ox as exemplified by different classes of NOS inhibitors. 12 -16 Binding affinity for iNOS was also observed for the simple 7 derivative 4-methoxy-2-methyls u Ifanylmethyl-pyrid i ne (10; plC so = 6.81). As shown in Table 2 , the introduction of a second methoxy group in the 3-or 5-position of the pyridine ring resulted in a complete loss of iNOS-affi nity (11, 12; iNOS: plC so <4). Interestingly, modifications of the imidazo[ 4,5-b ]pyridine ring system also significantly affect th e iNOS affin ity as demonstrated by the imidazo[4,5-c]pyridine derivative 8 (iNOS: plC so = 4.31) and the imidazobenzene ana logue 9 (iNOS: plC so = 4.97). This initial structure-activity relationship (SAR) prompted us to use 4-methoxypyridine in combination with the imidazo[4,5-b]pyridine as templates for further optimization. The resulting analogue BYK191 023 17 (Table 3) showed both an improved iNOS-affinity (pJC so = 7.09) and selectivity profile (nNOS: plC so = 4.86; eNOS: plC so = 3.95), respectively?4 A slightly reduced potency was observed for the 6-bromine-(18; iNOS: plC so = 6.73) and the 7-methyl-derivative (20; iNOS: plC so = 6.84) of 17. The drop in binding affinity was even more pronounced by the introduction of a 5-methoxy group (19; iNOS: ple so = 6.42) and by 5,7-dimethyl substitution (21; iNOS : pIC so = 5.64). Taken together, these results indicate limited space in the 5-position for further introduction of substituents. Therefore, we focused our efforts to improve potency on the 6-and 7-position of 17.
We next determined the binding position of 17 within the L-arginine binding site by X-ray crystallography using murine iNOSox.R. 26 The 4-methoxypyridine ring is inserted into the guanidinium binding site bearing n-stacking interactions to the heme (Fi g. 2). An additional hydrogen bond to Glu37l is formed between the OE1-atom and an adjacent water molecule (watl), which is also involved in an H-bond (3 .1 A) to the N3-atom of the imidazo suggested, that the inhibitors are likely to be neutral in solution at the applied assay conditions. However, pK. values of ligands can be shifted in protein binding sites due to the electrostatic influence of the protein's titratable groups in the direct environmenr. 29 For the complex of methotrexate (MTX) with dihydrofolate reductase (OHFR), a pK.-shift from 5.7 (apo) to 7.9 (complexed) was predicted in agreement with previous experimental results. 3lJ In a study from Astra-Zeneca researchers, in fact, tl;e X-ray structures of iNOS in complex with 4-methyl-2-aminopyridine and the 2amino-4-methoxypyridine-derivative 6 (AR-C133057XX) revealed a bidendate charge-interaction of the (protonated) 2-aminopyridine-group to Glu371. 19 Furthermore, the presence of a basic guanidine, amidino or isothiourea group has been proposed as a key recognition element in NOS inhibitors targeting the guanidine binding region. 3 1 We therefore predict, that the pK. assigned to the 4-methoxypyridine N-atom of 17 is shifted from 6.25 in solution towards higher values in the binding pocket of iNOS stabilizing appropriate protonation for salt-bridge interaction to Glu371 . The bottom part of the heterocyclic binding pocket is completed by the side chain of Arg382, which is hydrogen bonded to wat4 through its NH1-atom. Interestingly, the C5-atom of the imidazo [4,5-b] pyridine is in close contact (3.3 A) to the NH2-atom of Arg382 and readily explains the decrease in binding affinity of the 5-methoxy-(19: iNOS: plC so = 6.42) and of the 5,7-dimethylderivative (21: iNOS: plC so = 5.64) of 17. The upper part of the imidazo [4,5-b] pyridine binding pocket is less well defined, since the side chains of the proximal residues Ser256 and Gln257 are disordered in the electron density map. Therefore, the exact role of the Ser256 and Gln257 side chains in the recognition of the imidazo [ 4,5-b ] pyridine ring remains unclear. Both murine and human iNOS oxygenase domains show a high level of sequence identity (89%) and the amino acids involved in substrate and 17 binding are strictly conserved. In agreement with these structural similarities, the experimental K; of 17 towards the murine (pK; = 6.78) and human iNOS (pK; = 7,07) appears to be in the same range.23 When comparing the ligand binding sites of murine iNOS ox ·17 and human iNOSox'L-arginine, significant conformational differences of Arg260 (hiNOS: Arg266) and Gln257 (hi-NOS: Gln263) adjacent to the imidazo(4,S-b)pyridine ring can be observed (Fig. 3) , This region has been described as 'GIn specificity pocket' promoting isoform selectivity by sequence specific plasticity of the binding site. 32 In this study, bulky derivatives of 6 induced conformational changes in human iNOS involving the rotation of Gln263 from a 'GIn-closed' position (L-arginine bound) towards a 'G lnopen' position (inhibitor bound), Although the corresponding Gln2S7 is not defined in the murine iNOS ox ,1 7 structure, the side chain conformation of Arg260 corresponds to Arg266 in the 'Glnopen' structure of human iNOS (Fig, 3) . The induced fit of Arg266 is supplemented by the rotation of Asn283 (nNOS: Asn498, eNOS : Asn 267), which is supported by less bulkier 3rd shell amino acids in human iNOS (Val/Phe) compared to e NOS (Leu/lie) and nNOS (Leu/Phe). In the' murine iNOS ox ,17 structure, the rotation of Arg260 is tolerated by the presence of Thr277 and Ser256 in the vicinity resembling a 'GIn-open' conformation as in human iNOS, Taken together, we would expect distinct conformations of th e imidazo(4,S -b ]pyridine ring in eNOS and nNOS with disfavoured interactions, explaining the obselved isoform selectivity, Th e crystal structures of human NOS isoforms in complex with 17 would be of great value to address this hypothesis. We have recently demo nstrated, that 17 irreversibly inactivates murine iNOS by an NADPHand time-dependent mechanism leading to uncoupled electron transfer and heme loss.33 However, this time-dependent inhibition was ·not observed for nNOS, Structural differences in the binding site of 17 between the NOS isoforms might contribute in this inactivation mechanism.
Selected results of our subsequent SAR evaluation are summarized in Table 4 . In th e series of7-substituted 17 derivatives,a significant drop in iNOS binding affinity was obselved. The introduction of a 7-methoxy group resulted in a 1 O-fold reduction of potency (22; iNOS: plC so = 6.11) as well as the 7-ethoxy-methoxy- (23; iNOS: plC so = 6,29) and the 7-phenethyloxy-derivative (24: iNOS : plC so = 6.14) of 17. This mi ght be due to less favourable 4231 interactions displayed by these 7-s ubstituents in the corresponding part of the binding site as seen in our docking studies, In contrast, the exemplified 6-derivatives of 17 having an-butyl (25; iNOS: plC so = 7.26) and phenyl substituent (26; iNOS: plC so = 7.41) both demonstrate a gain in iNOS affinity, The murine iNOS ox ,17 structure indicates a hydrophobic contact area formed by Trp84 (human iNOS: Trp90), ,Met114 (Met120), Ser256 (Ala262), Arg260 (Arg266) within 8 A distance to the 6-position of the imidazo(4,S-b )pyridine ring (Fig, 4) . This hydrophobic region is probably addressed by the l1-butyl and phenyl substituents of 25 Figure 4 . Connolly surface coloured by lipophilic potential (green: polar, brown: hydrophobic) calculated for the X-ray structure of murine iNOS (magenta) in complex with 17 indicates a hydrophobic contact area formed by Trp84, Met114, Ser256, Arg260, This area (dotted circle) is adressed by, for example, n-butyl and phenyl substituents in the 6-position of the imidazo [4,5-b ] pyridine (marked by an arrow) leading to improved iNOS affin ity, Table 5 Pharmacokinetic data and CYP 1'450 isoform profile (pIC sa ) Entry Structure 17 and 26 leading to enhanced iNOS affinity and demonstrating a guideline for further structure-based optimization. BYK 191023 17 as representative of th e discussed imidazo [4,5-bJpyridines displayed favorable pharmacokinetic parameters along with a clean CYP P450 isoform inhibition profile (Table 5) and drug-like physicochemical properties (data not shown). A comprehensive pharmacological assessment for 17 had been publi shed elsewhere, 23, 34, 35 In conclusion, we have demonstrated va luable structural insights for id entifying and evaluating structure-activity relationships of potent and isoform selective iNOS inhibitors starting from initial HTS results. Binding mode of 17 guided us to rationalize our experimental SAR and to d rive the design of inhibitors. iNOS inhibitors 17-26 represent selected structures capa ble of illustrating rationals and conclusions. Moreover, we described a straightforward synthetic access, favorab le pharmacokinetic and CYP P450 data of the lead structure 17 as representative of th e introduced iNOS inhibitor class.
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